MDA-MB-415 Xenograft Model Service for Breast Cancer

The MDA-MB-415 xenograft model establishes a highly translational in vivo platform specifically optimized for evaluating candidate therapies targeting PIK3CA-mutated, hormone-receptor-positive human breast cancers. Alfa Cytology delivers a comprehensive, end-to-end MDA-MB-415 xenograft model service, integrating fully authenticated cellular assets with standardized procedural protocols and customized endocrine supports to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-415 Xenograft Model for Breast Cancer

The MDA-MB-415 cell line is a molecularly distinct human mammary carcinoma model highly valued in preclinical oncology for its accurate representation of luminal-type breast adenocarcinoma. Originally isolated from the pleural effusion of a patient with advanced, progressive disease, this model phenotypically expresses ER and possesses a critically relevant homozygous mutation in the PIK3CA gene (specifically the oncogenic H1047R hot-spot mutation in the kinase domain). The hyperactivation of the PI3K/AKT/mTOR pathway driven by this genetic hallmark, operating in tandem with classical estrogen receptor signaling cascades, makes the MDA-MB-415 model an indispensable preclinical test matrix for investigating endocrine therapy resistance mechanisms and for validating novel PI3K inhibitors, AKT inhibitors, mTOR antagonists, and combination regimens involving novel SERDs or CDK4/6 inhibitors.

When established in vivo as a xenograft in immunodeficient mice, MDA-MB-415 cells develop into solid, epithelial-like tumors that reliably preserve the precise histological architecture, receptor presentation, and mutational signatures of clinical hormone-receptor-positive malignancies.

Fig 1. Functional analysis in BC cell lines using knockdown cells. (Soeda I, et al., 2025)

Cell Line Information: MDA-MB-415

The MDA-MB-415 cell line maintains a stable epithelial-like morphology in vitro and reliably preserves its primary ER expression and PIK3CA mutational hallmarks upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-415 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, estradiol supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ER status and PI3K pathway markers and PK/PD profiling. Leveraging our expertise in PIK3CA-mutated luminal breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-415 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-415 xenograft model:

• Cell Culture & Quality Control: MDA-MB-415 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Adaptation & Estrogen Priming: Standardized immunocompromised mice are selected based on study design and pre-implanted with controlled-release estradiol pellets to support the hormone-dependent growth components of the line. Animals are acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-415 cells is prepared and blended with a verified biological matrix carrier to overcome slow growth barriers and maximize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-415 Xenograft Model Construction Workflow

Case Study - MDA-MB-415 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-415 xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule PI3Kα selective inhibitor designed to overcome endocrine therapy resistance in ER+ breast cancer. Under optimized modeling conditions featuring calibrated estradiol supplementation, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your PIK3CA-mutated, hormone-dependent breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and hormone-supplementation protocols, ensuring uniform tumor growth and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, pathway biomarker profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against PIK3CA-mutated, hormone-dependent breast cancer using the robust MDA-MB-415 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.